Omeros (OMER) Prices $40M Common Stock Offering at $11.50/Share

August 11, 2016 10:50 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to the satisfaction of customary closing conditions.

Cantor Fitzgerald & Co. is acting as the sole underwriter for the offering.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, manufacturing development and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions, and supporting the continued commercialization of OMIDRIA. The net offering proceeds may also be used for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

A registration statement on Form S-3 (File No. 333-201581) relating to the securities was filed with the Securities and Exchange Commission on January 16, 2015 and amended on March 15, 2016. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus were filed with the Securities and Exchange Commission on August 10, 2016. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the website of the Securities and Exchange Commission at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at prospectus@cantor.com.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings

Related Entities

Cantor Fitzgerald, S3

Add Your Comment